Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.

Novartis announced the company’s financial results for the second quarter and first half of 2024.

Novartis announced the company’s financial results for the first quarter of 2023.

Novartis announces the company’s fourth quarter and 2020 full year financial results.